World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
43229
World Ranking
6240
National Ranking
3330

William Plunkett publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where William Plunkett sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 444 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

William Plunkett D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where William Plunkett sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

William Plunkett is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on chronic lymphocytic leukemia (CLL) and related hematological malignancies within the broader field of medicine. The main fields of study for their work include genetics, immunology, molecular biology, pathology and forensic medicine, and oncology.

Their research topics encompass chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, advanced breast cancer therapies, cancer-related molecular pathways, phagocytosis and immune regulation, and chronic myeloid leukemia treatments.

William Plunkett has contributed to several notable publications. Some recent papers are:

  • "Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia," 2021, published in JAMA Oncology
  • "Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up," 2023, published in Blood
  • "Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations," 2021, published in Leukemia
  • "Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells," 2022, published in Leukemia
  • "The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action," 2021, published in Blood Cancer Journal

Their frequent co-authors include:

  • William G. Wierda
  • Michael J. Keating
  • Philip A. Thompson
  • Varsha Gandhi
  • Nitin Jain

William Plunkett has published primarily in well-established journals in hematology and oncology. The venues where they have the most publications are:

  • Blood
  • Cancer Research
  • Leukemia
  • JAMA Oncology
  • Blood Cancer Journal

In recognition of their contributions to science, William Plunkett was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2012.

Best Publications

  • Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

    Kenneth P. Olive;Michael A. Jacobetz;Christian J. Davidson;Aarthi Gopinathan;Aarthi Gopinathan

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

    Peng Huang;Sherri Chubb;Sherri Chubb;Larry W. Hertel;Gerald B. Grindey

  • Superoxide dismutase as a target for the selective killing of cancer cells

    Peng Huang;Li Feng;Elizabeth A. Oldham;Michael J. Keating

  • Gemcitabine : metabolism, mechanisms of action, and self-potentiation

    W. Plunkett;Peng Huang;Yi-Zheng Xu;V. Heinemann

  • Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine

    Volker Heinemann;Larry W. Hertel;Gerald B. Grindey;William K Plunkett

  • Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

    M. J. Keating;Hagop M Kantarjian;M. Talpaz;J. Redman

  • Inhibition of Mitochondrial Respiration A NOVEL STRATEGY TO ENHANCE DRUG-INDUCED APOPTOSIS IN HUMAN LEUKEMIA CELLS BY A REACTIVE OXYGEN SPECIES-MEDIATED MECHANISM

    Helene Pelicano;Li Feng;Yan Zhou;Jennifer S. Carew

  • Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

    Margaret Tempero;William Plunkett;Veronique Ruiz Van Haperen;John Hainsworth

  • Gemcitabine: preclinical pharmacology and mechanisms of action.

    W. Plunkett;P. Huang;C. E. Searcy;V. Gandhi

  • Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

    Philip A. Thompson;Constantine S. Tam;Susan M. O'Brien;William G. Wierda

  • Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

    V. Heinemann;Yi-Zheng Xu;S. Chubb;A. Sen

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

    Varsha Gandhi;Elihu Estey;Michael J. Keating;William Plunkett

  • TRIM24 links a non-canonical histone signature to breast cancer

    Wen Wei Tsai;Zhanxin Wang;Teresa T. Yiu;Teresa T. Yiu;Kadir C. Akdemir

  • Cellular Elimination of 2′,2′-Difluorodeoxycytidine 5′-Triphosphate: A Mechanism of Self-Potentiation

    Volker Heinemann;Yi-Zheng Xu;Sherri Chubb;Alina Sen

  • Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.

    Yan Zhou;Elizabeth O. Hileman;William Plunkett;Michael J. Keating

  • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

    Hagop M Kantarjian;Varsha Gandhi;Jorge Cortes;Srdan Verstovsek

  • Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine

    L. E. Robertson;Sherri Chubb;Raymond E. Meyn;Michael Story

Frequent Co-Authors

Varsha Gandhi
Varsha Gandhi The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Jorge E. Cortes
Jorge E. Cortes Augusta University
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare careers beyond traditional medical school, there are several flexible options available. For those coming from non-nursing backgrounds, direct entry msn programs for non-nursing majors offer a pathway to advanced nursing credentials without the need for a prior nursing degree. These programs can accelerate your entry into the field and expand your career possibilities.

If you prefer starting with an entry-level role, pursuing an Associate Degree in Nursing (ADN) offers a more accessible route. Many choose adn programs for their shorter duration and practical focus, providing a solid foundation in nursing skills and quicker workforce entry.

Not all healthcare paths involve patient care. If you're interested in the administrative side, consider accredited medical billing and coding online schools. These programs offer hands-on training and often financial aid to help you start a stable career in healthcare administration.

Lastly, some nursing programs make entry even more accessible. Are you wondering, do I need to take the TEAS test for LPN? Many schools now offer routes that don’t require standardized exams like TEAS or HESI, streamlining the admissions process and helping you start your nursing journey sooner.

Best Scientists Citing William Plunkett

Trending Scientists

Recently Published Articles